Invention Grant
- Patent Title: LRRK2 inhibitors
-
Application No.: US18049802Application Date: 2022-10-26
-
Publication No.: US11780851B2Publication Date: 2023-10-10
- Inventor: Thomas Jensen , Mikkel Jessing , Wanwan Yu , David Rodriguez Diaz , Jacob Nielsen , Christopher Richard Jones , Thomas Andersen , Mikkel Fog Jacobsen
- Applicant: H. Lundbeck A/S , Vernalis (R&D) Limited
- Applicant Address: DK Valby
- Assignee: H. Lundbeck A/S
- Current Assignee: H. Lundbeck A/S
- Current Assignee Address: DK Valby
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: EP 204970 2021.10.27 EP 201380 2022.10.13
- Main IPC: C07D498/22
- IPC: C07D498/22
Abstract:
The present invention is directed to compounds of formula I
The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.
Public/Granted literature
- US20230144725A1 LRRK2 INHIBITORS Public/Granted day:2023-05-11
Information query
